Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo

Clinical and Experimental Immunology

Volumn 173, Issue 2, 2013, Pages 179-183

  Sanchez Sosa, S ^a   Aguirre Lombardo, M ^b   Jimenez Brito, G ^c   Ruiz Arguelles A ^a,b  

^a UNIVERSIDAD POPULAR AUTÓNOMA DEL ESTADO DE PUEBLA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c El Colegio de Puebla   (Mexico)

Author keywords

immunopathogenesis; immunopathology; lymphoid infiltrates; vitiligo

Indexed keywords

CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; T6 ANTIGEN;

ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEPIGMENTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOID CELL; MELANOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VITILIGO;

IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; LYMPHOID INFILTRATES; VITILIGO;

ANTIGENS, CD; AUTOANTIGENS; AUTOIMMUNITY; CELL SEPARATION; DENDRITIC CELLS; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MELANOCYTES; SKIN; VITILIGO;

EID: 84880020693     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12096     Document Type: Article

References (39)

1. Ruiz-Argüelles A, Jimenez-Brito G, Reyes-Izquierdo P, Pérez-Romano B, Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 2007; 29:281-286.
2. Van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81:1061-1067.
3. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38:647-666.
4. Uchi H, Stan R, Turk MJ etal. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006; 90:215-241.
5. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Exp Rev Mol Med 2001; 3:1-22.
6. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA. Childhood vitiligo. J Am Acad Dermatol 1987; 16:948-954.
7. Park S, Albert DM, Bolognia JL. Ocular manifestations of pigmentary disorders. Dermatol Clin 1992; 10:609-622.
8. Ochi Y, DeGroot LJ. Vitiligo in Graves' disease. Ann Intern Med 1969; 71:935-940.
9. Gould IM, Gray RS, Urbaniak SJ, Elton RA, Duncan LJ. Vitiligo in diabetes mellitus. Br J Dermatol 1985; 113:153-155.
10. Jiménez-Brito G, Garza-de-La-Peña E, Pérez-Romano B, Ruiz-Argüelles A. Serum antibodies to melanocytes in patients with vitiligo are predictors of disease progression. Skin Med J 2012; 10: in press.
11. Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996; 18:371-378.
12. Hill LL, Shreedhar VK, Kripke ML, Owen Schaub LB. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999; 189:1285-1294.
13. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N. The role of tyrosine in autoimmune vitiligo. Lancet 1994; 344:1049-1052.
14. Gulhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105:683-686.
15. Alghamdi KM, Khurrum H, Taieb H, Ezzedibe K. Treatment of generalized vitiligo with anti TNF-α agents. J Drugs Dermatol 2012; 11:534-539.
16. Pagliarello C, Paradisi A. Topical tacrolimus is useful for avoiding suction-blister epidermal grafting depigmentation in non segment vitiligo: a case report. Acta Derm Venereol 2012; 92:181-182.
17. Nisticó S, Chiricozzi A, Saraceno R, Schipiani C, Chimenti S. Vitiligo treatment with monochromatic excimer light and tacrolimus: results of an open randomized controlled trial. Photomed Laser Surg 2012; 30:26-30.
18. Zmijewski AJ, Slominski AT. Neuroendocrinology of the skin: an overview and selective analysis. Dermatoendocrinol 2011; 3:3-10.
19. Alarcón-Segovia D, Ruíz-Argüelles A, Llorente L. Broken dogma: penetration of autoantibodies into living cells. Immunol Today 1996; 17:163-164.
20. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Alarcón-Segovia D. Antibody penetration into living cells: pathogenic, preventive and immunotherapeutic implications. Curr Pharm Des 2003; 9:1881-1887.
21. Ruiz-Argüelles A, Pérez-Romano B, Llorente L, Alarcón-Segovia D, Castellanos JM. Penetration of anti-DNA antibodies into immature live cells. J Autoimmun 1998; 11:547-556.
22. Portales-Pérez D, Alarcón-Segovia D, Llorente L etal. Penetrating antiI-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells. J Autoimmun 1998; 11:563-571.
23. Rivadeneyra-Espinoza L, Ruiz-Argüelles A. Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways. J Autoimmun 2006; 26:52-56.
24. Shcmidt-Acevedo S, Perez-Romano B, Ruiz-Argüelles A. LE cells result from phagocytosis of apoptotic bodies induced by antinuclear antibodies. J Autoimmun 2000; 15:15-20.
25. Alarcón-Segovia D, Llorente L, Ruiz-Argüelles A. The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. J Autoimmun 1996; 9:295-300.
26. Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L. Antibody penetration into living cells III. Effect of anti-ribonucleoprotein IgG on the cell cycle of human peripheral blood mononuclear cells. Clin Immunol Immunopathol 1982; 23:22-26.
27. Joyner A, Wall N. Immunohistochemistry of whole-mount mouse embryos. CSH Protoc 2008; 2008:pdb.prot4820.
28. Burnett R, Guichard Y, Barale E. Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview. Toxicology 1997; 119:83-93.
29. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42:405-426.
30. Shoenfeld Y, Cervera R, Gershwin ME, eds. Diagnostic criteria in autoimmune disease. Totowa, NJ: Humana Press, 2008.
31. Perl A. Pathogenesis and spectrum of autoimmunity. Methods Mol Biol 2012; 900:1-9.
32. Hossain A, Radwan FF, Doonan BP etal. A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. Apoptosis 2012; 17:1066-1078.
33. Wang CQ, Cruz-Iñigo AE, Fuentes-Duculan J etal. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS ONE 2011; 25:e18907.
34. Schwartz RH. Natural regulatory T cells and self tolerance. Nat Immunol 2005; 6:327-330.
35. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13:108-116.
36. Rouse BT. Regulatory T cells in health and disease. J Intern Med 2007; 262:78-95.
37. Gray D, Gray M. What are regulatory B cells. Eur J Immunol 2010; 40:2677-2679.
38. Porter J, Beuf AH, Lerner AB, Nordlund JJ. Response to cosmetic disfigurement: patients with vitiligo. Cutis 1987; 39:493-494.
39. Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry 1979; 1:73-77.